These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

402 related articles for article (PubMed ID: 27418107)

  • 1. TKI combination therapy: strategy to enhance dasatinib uptake by inhibiting Pgp- and BCRP-mediated efflux.
    D'Cunha R; Bae S; Murry DJ; An G
    Biopharm Drug Dispos; 2016 Oct; 37(7):397-408. PubMed ID: 27418107
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ingredients in fruit juices interact with dasatinib through inhibition of BCRP: a new mechanism of beverage-drug interaction.
    Fleisher B; Unum J; Shao J; An G
    J Pharm Sci; 2015 Jan; 104(1):266-75. PubMed ID: 25418056
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of 5,7-dimethoxyflavone on Bcrp1-mediated transport of sorafenib in vitro and in vivo in mice.
    Bae S; D'Cunha R; Shao J; An G
    Eur J Pharm Sci; 2018 May; 117():27-34. PubMed ID: 29425861
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro assessment of the interactions of dopamine β-hydroxylase inhibitors with human P-glycoprotein and Breast Cancer Resistance Protein.
    Bicker J; Alves G; Fortuna A; Soares-da-Silva P; Falcão A
    Eur J Pharm Sci; 2018 May; 117():35-40. PubMed ID: 29428540
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tyrosine kinase inhibitors influence ABCG2 expression in EGFR-positive MDCK BCRP cells via the PI3K/Akt signaling pathway.
    Pick A; Wiese M
    ChemMedChem; 2012 Apr; 7(4):650-62. PubMed ID: 22354538
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nilotinib Alters the Efflux Transporter-Mediated Pharmacokinetics of Afatinib in Mice.
    D'Cunha RR; Murry DJ; An G
    J Pharm Sci; 2019 Oct; 108(10):3434-3442. PubMed ID: 31163185
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Interaction of nilotinib, dasatinib and bosutinib with ABCB1 and ABCG2: implications for altered anti-cancer effects and pharmacological properties.
    Hegedus C; Ozvegy-Laczka C; Apáti A; Magócsi M; Német K; Orfi L; Kéri G; Katona M; Takáts Z; Váradi A; Szakács G; Sarkadi B
    Br J Pharmacol; 2009 Oct; 158(4):1153-64. PubMed ID: 19785662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib.
    Dohse M; Scharenberg C; Shukla S; Robey RW; Volkmann T; Deeken JF; Brendel C; Ambudkar SV; Neubauer A; Bates SE
    Drug Metab Dispos; 2010 Aug; 38(8):1371-80. PubMed ID: 20423956
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nilotinib (AMN107, Tasigna) reverses multidrug resistance by inhibiting the activity of the ABCB1/Pgp and ABCG2/BCRP/MXR transporters.
    Tiwari AK; Sodani K; Wang SR; Kuang YH; Ashby CR; Chen X; Chen ZS
    Biochem Pharmacol; 2009 Jul; 78(2):153-61. PubMed ID: 19427995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro characterization of axitinib interactions with human efflux and hepatic uptake transporters: implications for disposition and drug interactions.
    Reyner EL; Sevidal S; West MA; Clouser-Roche A; Freiwald S; Fenner K; Ullah M; Lee CA; Smith BJ
    Drug Metab Dispos; 2013 Aug; 41(8):1575-83. PubMed ID: 23729661
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro and in vivo evaluation of WK-X-34, a novel inhibitor of P-glycoprotein and BCRP, using radio imaging techniques.
    Jekerle V; Klinkhammer W; Scollard DA; Breitbach K; Reilly RM; Piquette-Miller M; Wiese M
    Int J Cancer; 2006 Jul; 119(2):414-22. PubMed ID: 16646006
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of sodium-independent and sodium-dependent nucleobase transport activities by tyrosine kinase inhibitors.
    Damaraju VL; Kuzma M; Cass CE; Sawyer MB
    Cancer Chemother Pharmacol; 2015 Nov; 76(5):1093-8. PubMed ID: 26330332
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel tetrahydroisoquinolin-ethyl-phenylamine based multidrug resistance inhibitors with broad-spectrum modulating properties.
    Jekerle V; Klinkhammer W; Reilly RM; Piquette-Miller M; Wiese M
    Cancer Chemother Pharmacol; 2007 Jan; 59(1):61-9. PubMed ID: 16636798
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Aristolochic acid I is a substrate of BCRP but not P-glycoprotein or MRP2.
    Ma L; Qin Y; Shen Z; Bi H; Hu H; Huang M; Zhou H; Yu L; Jiang H; Zeng S
    J Ethnopharmacol; 2015 Aug; 172():430-5. PubMed ID: 26183576
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A new mechanism for increasing the oral bioavailability of scutellarin with Cremophor EL: Activation of MRP3 with concurrent inhibition of MRP2 and BCRP.
    Xiao L; Yi T; Chen M; Lam CW; Zhou H
    Eur J Pharm Sci; 2016 Oct; 93():456-67. PubMed ID: 27586020
    [TBL] [Abstract][Full Text] [Related]  

  • 16. siRNA-mediated knock-down of P-glycoprotein expression reveals distinct cellular disposition of anticancer tyrosine kinases inhibitors.
    Haouala A; Rumpold H; Untergasser G; Buclin T; Ris HB; Widmer N; Decosterd LA
    Drug Metab Lett; 2010 Apr; 4(2):114-9. PubMed ID: 20446917
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The antiepileptic drug lamotrigine is a substrate of mouse and human breast cancer resistance protein (ABCG2).
    Römermann K; Helmer R; Löscher W
    Neuropharmacology; 2015 Jun; 93():7-14. PubMed ID: 25645391
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).
    Kort A; van Hoppe S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Mol Pharm; 2017 Oct; 14(10):3258-3268. PubMed ID: 28880088
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences.
    Azzariti A; Porcelli L; Simone GM; Quatrale AE; Colabufo NA; Berardi F; Perrone R; Zucchetti M; D'Incalci M; Xu JM; Paradiso A
    Cancer Chemother Pharmacol; 2010 Jan; 65(2):335-46. PubMed ID: 19495754
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Interaction Studies of Resolvin E1 Analog (RX-10045) with Efflux Transporters.
    Cholkar K; Trinh HM; Vadlapudi AD; Wang Z; Pal D; Mitra AK
    J Ocul Pharmacol Ther; 2015 May; 31(4):248-55. PubMed ID: 25844889
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.